Minimal Residual Disease in Acute Myeloid Leukemia of Adults

Determination, Prognostic Impact and Clinical Applications

Maria Ilaria Del Principe, Francesco Buccisano, Luca Maurillo, Giuseppe Sconocchia, Mariagiovanna Cefalo, Maria Irno Consalvo, Chiara Sarlo, Consuelo Conti, Giovanna De Santis, Eleonora De Bellis, Ambra Di Veroli, Patrizia Palomba, Cristina Attrotto, Annagiulia Zizzari, Giovangiacinto Paterno, Maria Teresa Voso, Giovanni Del Poeta, Francesco Lo-Coco, William Arcese, Sergio Amadori & 1 others Adriano Venditti

Research output: Contribution to journalArticle

Abstract

Pretreatment assessment of cytogenetic/genetic signature of acute myeloid leukemia (AML) has been consistently shown to play a major prognostic role but also to fail at predicting outcome on individual basis, even in low-risk AML. Therefore, we are in need of further accurate methods to refine the patients' risk allocation process, distinguishing more adequately those who are likely to recur from those who are not. In this view, there is now evidence that the submicroscopic amounts of leukemic cells (called minimal residual disease, MRD), measured during the course of treatment, indicate the quality of response to therapy. Therefore, MRD might serve as an independent, additional biomarker to help to identify patients at higher risk of relapse. Detection of MRD requires the use of highly sensitive ancillary techniques, such as polymerase chain reaction (PCR) and multiparametric flow cytometry(MPFC). In the present manuscript, we will review the current approaches to investigate MRD and its clinical applications in AML management.

Original languageEnglish
Pages (from-to)e2016052
JournalMediterranean Journal of Hematology and Infectious Diseases
Volume8
Issue number1
DOIs
Publication statusPublished - 2016

Fingerprint

Residual Neoplasm
Acute Myeloid Leukemia
Manuscripts
Cytogenetics
Flow Cytometry
Biomarkers
Recurrence
Polymerase Chain Reaction
Therapeutics

Keywords

  • Review
  • Journal Article

Cite this

Minimal Residual Disease in Acute Myeloid Leukemia of Adults : Determination, Prognostic Impact and Clinical Applications. / Del Principe, Maria Ilaria; Buccisano, Francesco; Maurillo, Luca; Sconocchia, Giuseppe; Cefalo, Mariagiovanna; Consalvo, Maria Irno; Sarlo, Chiara; Conti, Consuelo; De Santis, Giovanna; De Bellis, Eleonora; Veroli, Ambra Di; Palomba, Patrizia; Attrotto, Cristina; Zizzari, Annagiulia; Paterno, Giovangiacinto; Voso, Maria Teresa; Del Poeta, Giovanni; Lo-Coco, Francesco; Arcese, William; Amadori, Sergio; Venditti, Adriano.

In: Mediterranean Journal of Hematology and Infectious Diseases, Vol. 8, No. 1, 2016, p. e2016052.

Research output: Contribution to journalArticle

Del Principe, MI, Buccisano, F, Maurillo, L, Sconocchia, G, Cefalo, M, Consalvo, MI, Sarlo, C, Conti, C, De Santis, G, De Bellis, E, Veroli, AD, Palomba, P, Attrotto, C, Zizzari, A, Paterno, G, Voso, MT, Del Poeta, G, Lo-Coco, F, Arcese, W, Amadori, S & Venditti, A 2016, 'Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications', Mediterranean Journal of Hematology and Infectious Diseases, vol. 8, no. 1, pp. e2016052. https://doi.org/10.4084/MJHID.2016.052
Del Principe, Maria Ilaria ; Buccisano, Francesco ; Maurillo, Luca ; Sconocchia, Giuseppe ; Cefalo, Mariagiovanna ; Consalvo, Maria Irno ; Sarlo, Chiara ; Conti, Consuelo ; De Santis, Giovanna ; De Bellis, Eleonora ; Veroli, Ambra Di ; Palomba, Patrizia ; Attrotto, Cristina ; Zizzari, Annagiulia ; Paterno, Giovangiacinto ; Voso, Maria Teresa ; Del Poeta, Giovanni ; Lo-Coco, Francesco ; Arcese, William ; Amadori, Sergio ; Venditti, Adriano. / Minimal Residual Disease in Acute Myeloid Leukemia of Adults : Determination, Prognostic Impact and Clinical Applications. In: Mediterranean Journal of Hematology and Infectious Diseases. 2016 ; Vol. 8, No. 1. pp. e2016052.
@article{e836df1a59774db1b325414f54b8ad9b,
title = "Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications",
abstract = "Pretreatment assessment of cytogenetic/genetic signature of acute myeloid leukemia (AML) has been consistently shown to play a major prognostic role but also to fail at predicting outcome on individual basis, even in low-risk AML. Therefore, we are in need of further accurate methods to refine the patients' risk allocation process, distinguishing more adequately those who are likely to recur from those who are not. In this view, there is now evidence that the submicroscopic amounts of leukemic cells (called minimal residual disease, MRD), measured during the course of treatment, indicate the quality of response to therapy. Therefore, MRD might serve as an independent, additional biomarker to help to identify patients at higher risk of relapse. Detection of MRD requires the use of highly sensitive ancillary techniques, such as polymerase chain reaction (PCR) and multiparametric flow cytometry(MPFC). In the present manuscript, we will review the current approaches to investigate MRD and its clinical applications in AML management.",
keywords = "Review, Journal Article",
author = "{Del Principe}, {Maria Ilaria} and Francesco Buccisano and Luca Maurillo and Giuseppe Sconocchia and Mariagiovanna Cefalo and Consalvo, {Maria Irno} and Chiara Sarlo and Consuelo Conti and {De Santis}, Giovanna and {De Bellis}, Eleonora and Veroli, {Ambra Di} and Patrizia Palomba and Cristina Attrotto and Annagiulia Zizzari and Giovangiacinto Paterno and Voso, {Maria Teresa} and {Del Poeta}, Giovanni and Francesco Lo-Coco and William Arcese and Sergio Amadori and Adriano Venditti",
year = "2016",
doi = "10.4084/MJHID.2016.052",
language = "English",
volume = "8",
pages = "e2016052",
journal = "Mediterranean Journal of Hematology and Infectious Diseases",
issn = "2035-3006",
publisher = "Universita Cattolica del Sacro Cuore",
number = "1",

}

TY - JOUR

T1 - Minimal Residual Disease in Acute Myeloid Leukemia of Adults

T2 - Determination, Prognostic Impact and Clinical Applications

AU - Del Principe, Maria Ilaria

AU - Buccisano, Francesco

AU - Maurillo, Luca

AU - Sconocchia, Giuseppe

AU - Cefalo, Mariagiovanna

AU - Consalvo, Maria Irno

AU - Sarlo, Chiara

AU - Conti, Consuelo

AU - De Santis, Giovanna

AU - De Bellis, Eleonora

AU - Veroli, Ambra Di

AU - Palomba, Patrizia

AU - Attrotto, Cristina

AU - Zizzari, Annagiulia

AU - Paterno, Giovangiacinto

AU - Voso, Maria Teresa

AU - Del Poeta, Giovanni

AU - Lo-Coco, Francesco

AU - Arcese, William

AU - Amadori, Sergio

AU - Venditti, Adriano

PY - 2016

Y1 - 2016

N2 - Pretreatment assessment of cytogenetic/genetic signature of acute myeloid leukemia (AML) has been consistently shown to play a major prognostic role but also to fail at predicting outcome on individual basis, even in low-risk AML. Therefore, we are in need of further accurate methods to refine the patients' risk allocation process, distinguishing more adequately those who are likely to recur from those who are not. In this view, there is now evidence that the submicroscopic amounts of leukemic cells (called minimal residual disease, MRD), measured during the course of treatment, indicate the quality of response to therapy. Therefore, MRD might serve as an independent, additional biomarker to help to identify patients at higher risk of relapse. Detection of MRD requires the use of highly sensitive ancillary techniques, such as polymerase chain reaction (PCR) and multiparametric flow cytometry(MPFC). In the present manuscript, we will review the current approaches to investigate MRD and its clinical applications in AML management.

AB - Pretreatment assessment of cytogenetic/genetic signature of acute myeloid leukemia (AML) has been consistently shown to play a major prognostic role but also to fail at predicting outcome on individual basis, even in low-risk AML. Therefore, we are in need of further accurate methods to refine the patients' risk allocation process, distinguishing more adequately those who are likely to recur from those who are not. In this view, there is now evidence that the submicroscopic amounts of leukemic cells (called minimal residual disease, MRD), measured during the course of treatment, indicate the quality of response to therapy. Therefore, MRD might serve as an independent, additional biomarker to help to identify patients at higher risk of relapse. Detection of MRD requires the use of highly sensitive ancillary techniques, such as polymerase chain reaction (PCR) and multiparametric flow cytometry(MPFC). In the present manuscript, we will review the current approaches to investigate MRD and its clinical applications in AML management.

KW - Review

KW - Journal Article

U2 - 10.4084/MJHID.2016.052

DO - 10.4084/MJHID.2016.052

M3 - Article

VL - 8

SP - e2016052

JO - Mediterranean Journal of Hematology and Infectious Diseases

JF - Mediterranean Journal of Hematology and Infectious Diseases

SN - 2035-3006

IS - 1

ER -